| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypoplastic Left Heart Syndrome | 19 | 2025 | 271 | 5.100 |
Why?
|
| Heart Defects, Congenital | 37 | 2025 | 1866 | 4.800 |
Why?
|
| Marfan Syndrome | 16 | 2025 | 149 | 4.510 |
Why?
|
| Loeys-Dietz Syndrome | 12 | 2025 | 42 | 4.190 |
Why?
|
| Echocardiography | 24 | 2025 | 1126 | 3.170 |
Why?
|
| Ultrasonography, Prenatal | 22 | 2025 | 1009 | 3.070 |
Why?
|
| Fetal Heart | 13 | 2025 | 135 | 2.920 |
Why?
|
| Turner Syndrome | 7 | 2022 | 45 | 2.280 |
Why?
|
| Transposition of Great Vessels | 6 | 2024 | 135 | 2.100 |
Why?
|
| Ehlers-Danlos Syndrome | 6 | 2025 | 52 | 1.970 |
Why?
|
| Arteries | 7 | 2025 | 222 | 1.830 |
Why?
|
| Skin Diseases, Genetic | 6 | 2025 | 21 | 1.780 |
Why?
|
| Heterotaxy Syndrome | 4 | 2024 | 63 | 1.770 |
Why?
|
| Joint Instability | 6 | 2025 | 59 | 1.730 |
Why?
|
| Aorta | 11 | 2025 | 552 | 1.630 |
Why?
|
| Vascular Malformations | 6 | 2025 | 112 | 1.610 |
Why?
|
| Aortic Valve | 10 | 2024 | 485 | 1.460 |
Why?
|
| Pregnancy | 35 | 2025 | 7557 | 1.380 |
Why?
|
| Aortic Aneurysm, Thoracic | 11 | 2025 | 705 | 1.370 |
Why?
|
| Retrospective Studies | 62 | 2025 | 17396 | 1.350 |
Why?
|
| Hospital Mortality | 13 | 2024 | 1081 | 1.310 |
Why?
|
| Aorta, Thoracic | 10 | 2025 | 540 | 1.310 |
Why?
|
| Female | 114 | 2025 | 70792 | 1.270 |
Why?
|
| Scimitar Syndrome | 2 | 2021 | 52 | 1.270 |
Why?
|
| Humans | 163 | 2025 | 132257 | 1.220 |
Why?
|
| Heart Septal Defects, Atrial | 4 | 2025 | 127 | 1.210 |
Why?
|
| Heart Ventricles | 13 | 2024 | 785 | 1.210 |
Why?
|
| Infant Mortality | 8 | 2024 | 179 | 1.180 |
Why?
|
| Aortic Diseases | 5 | 2025 | 197 | 1.180 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2025 | 185 | 1.180 |
Why?
|
| Heart Valve Diseases | 8 | 2024 | 178 | 1.100 |
Why?
|
| Cardiac Catheterization | 7 | 2025 | 671 | 1.100 |
Why?
|
| Infant, Newborn | 37 | 2024 | 8548 | 1.070 |
Why?
|
| Heart Transplantation | 8 | 2023 | 875 | 1.060 |
Why?
|
| Aortic Stenosis, Supravalvular | 2 | 2024 | 20 | 1.060 |
Why?
|
| Child | 60 | 2025 | 25784 | 1.040 |
Why?
|
| Premature Birth | 2 | 2022 | 418 | 1.040 |
Why?
|
| Mitral Valve | 4 | 2024 | 269 | 1.010 |
Why?
|
| Cardiac Surgical Procedures | 9 | 2024 | 1175 | 0.980 |
Why?
|
| Infant | 44 | 2025 | 13049 | 0.950 |
Why?
|
| Atrial Septum | 1 | 2025 | 19 | 0.940 |
Why?
|
| Adolescent | 49 | 2025 | 20561 | 0.900 |
Why?
|
| Gestational Age | 10 | 2025 | 1227 | 0.900 |
Why?
|
| Male | 84 | 2025 | 65019 | 0.880 |
Why?
|
| Registries | 17 | 2024 | 1591 | 0.880 |
Why?
|
| Prenatal Diagnosis | 6 | 2023 | 631 | 0.860 |
Why?
|
| Cor Triatriatum | 1 | 2024 | 10 | 0.860 |
Why?
|
| Williams Syndrome | 1 | 2024 | 41 | 0.850 |
Why?
|
| Child, Preschool | 38 | 2025 | 14736 | 0.850 |
Why?
|
| Tetralogy of Fallot | 6 | 2021 | 171 | 0.830 |
Why?
|
| Ventricular Function, Left | 4 | 2024 | 548 | 0.830 |
Why?
|
| Aortic Valve Stenosis | 3 | 2025 | 378 | 0.830 |
Why?
|
| Aortic Coarctation | 2 | 2021 | 107 | 0.810 |
Why?
|
| Pregnancy Complications | 5 | 2023 | 551 | 0.790 |
Why?
|
| Stroke Volume | 3 | 2024 | 536 | 0.790 |
Why?
|
| Pulmonary Valve | 2 | 2021 | 98 | 0.710 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2024 | 375 | 0.710 |
Why?
|
| Risk Factors | 29 | 2025 | 10946 | 0.700 |
Why?
|
| DiGeorge Syndrome | 1 | 2021 | 82 | 0.700 |
Why?
|
| Patient Discharge | 1 | 2025 | 511 | 0.690 |
Why?
|
| Connective Tissue Diseases | 4 | 2016 | 32 | 0.690 |
Why?
|
| Adult | 45 | 2025 | 31620 | 0.680 |
Why?
|
| Urinary Bladder Diseases | 1 | 2020 | 34 | 0.670 |
Why?
|
| Hospitalization | 5 | 2024 | 1902 | 0.670 |
Why?
|
| Down Syndrome | 3 | 2020 | 232 | 0.660 |
Why?
|
| Hospitals | 2 | 2021 | 439 | 0.660 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2018 | 108 | 0.650 |
Why?
|
| Abnormalities, Multiple | 4 | 2019 | 982 | 0.650 |
Why?
|
| Pulmonary Veins | 2 | 2021 | 172 | 0.650 |
Why?
|
| Mutation | 13 | 2024 | 6250 | 0.640 |
Why?
|
| Texas | 14 | 2024 | 3632 | 0.630 |
Why?
|
| Ebstein Anomaly | 4 | 2021 | 29 | 0.620 |
Why?
|
| Life Support Care | 1 | 2019 | 47 | 0.620 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2019 | 16 | 0.610 |
Why?
|
| United States | 21 | 2025 | 11675 | 0.600 |
Why?
|
| Receptors, Transforming Growth Factor beta | 2 | 2016 | 106 | 0.580 |
Why?
|
| Magnetic Resonance Imaging, Cine | 5 | 2024 | 175 | 0.580 |
Why?
|
| Vascular Resistance | 2 | 2018 | 195 | 0.580 |
Why?
|
| Trypanosoma cruzi | 10 | 1998 | 250 | 0.570 |
Why?
|
| Heart Atria | 4 | 2020 | 337 | 0.560 |
Why?
|
| Attitude to Health | 1 | 2019 | 261 | 0.560 |
Why?
|
| Phenotype | 15 | 2025 | 4540 | 0.560 |
Why?
|
| Disease Progression | 1 | 2024 | 2233 | 0.560 |
Why?
|
| Adenylyl Cyclases | 13 | 1999 | 67 | 0.560 |
Why?
|
| Influenza, Human | 1 | 2024 | 700 | 0.550 |
Why?
|
| Meningomyelocele | 1 | 2021 | 253 | 0.550 |
Why?
|
| Aortic Rupture | 2 | 2016 | 119 | 0.530 |
Why?
|
| Consensus | 2 | 2019 | 658 | 0.520 |
Why?
|
| Fetus | 6 | 2022 | 590 | 0.500 |
Why?
|
| Family | 1 | 2019 | 595 | 0.500 |
Why?
|
| Young Adult | 27 | 2025 | 9970 | 0.490 |
Why?
|
| Aortic Aneurysm | 3 | 2017 | 237 | 0.470 |
Why?
|
| Cerebrovascular Circulation | 1 | 2018 | 476 | 0.460 |
Why?
|
| Patient Care Team | 1 | 2019 | 576 | 0.460 |
Why?
|
| Time Factors | 13 | 2025 | 6452 | 0.460 |
Why?
|
| Oxygen | 1 | 2018 | 569 | 0.450 |
Why?
|
| Vascular Surgical Procedures | 2 | 2019 | 553 | 0.450 |
Why?
|
| Pulmonary Valve Stenosis | 3 | 2024 | 41 | 0.450 |
Why?
|
| Cesarean Section | 1 | 2018 | 417 | 0.450 |
Why?
|
| Tricuspid Valve | 3 | 2020 | 62 | 0.450 |
Why?
|
| Calcium Channels | 6 | 2001 | 163 | 0.440 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2019 | 462 | 0.440 |
Why?
|
| Mitral Valve Prolapse | 2 | 2024 | 37 | 0.440 |
Why?
|
| Myocardium | 10 | 2014 | 907 | 0.430 |
Why?
|
| Treatment Outcome | 22 | 2025 | 13031 | 0.430 |
Why?
|
| Databases, Factual | 6 | 2022 | 1234 | 0.430 |
Why?
|
| Fetal Therapies | 3 | 2020 | 82 | 0.430 |
Why?
|
| Collagen Type III | 3 | 2025 | 26 | 0.420 |
Why?
|
| Cardiomyopathies | 4 | 2024 | 509 | 0.400 |
Why?
|
| Cohort Studies | 11 | 2024 | 5176 | 0.390 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 6 | 2001 | 325 | 0.390 |
Why?
|
| Predictive Value of Tests | 7 | 2024 | 2314 | 0.390 |
Why?
|
| Receptors, Adrenergic, beta | 7 | 1996 | 52 | 0.390 |
Why?
|
| Chagas Cardiomyopathy | 9 | 1994 | 53 | 0.390 |
Why?
|
| Smad3 Protein | 2 | 2024 | 58 | 0.390 |
Why?
|
| Vertebral Artery | 2 | 2014 | 22 | 0.380 |
Why?
|
| Length of Stay | 5 | 2024 | 1382 | 0.380 |
Why?
|
| Chagas Disease | 8 | 1996 | 308 | 0.380 |
Why?
|
| Calcium | 9 | 2001 | 1080 | 0.370 |
Why?
|
| Verapamil | 5 | 1996 | 52 | 0.360 |
Why?
|
| Thoracic Surgery | 1 | 2013 | 166 | 0.360 |
Why?
|
| Tricuspid Valve Insufficiency | 3 | 2021 | 65 | 0.350 |
Why?
|
| DNA | 2 | 2020 | 1479 | 0.350 |
Why?
|
| Risk Assessment | 8 | 2025 | 3736 | 0.340 |
Why?
|
| Endothelium, Vascular | 8 | 2019 | 486 | 0.340 |
Why?
|
| Pedigree | 2 | 2024 | 1724 | 0.340 |
Why?
|
| Wolff-Parkinson-White Syndrome | 2 | 2022 | 73 | 0.330 |
Why?
|
| Echocardiography, Doppler, Color | 3 | 2021 | 115 | 0.320 |
Why?
|
| Umbilical Arteries | 2 | 2022 | 98 | 0.320 |
Why?
|
| Dilatation, Pathologic | 3 | 2021 | 89 | 0.320 |
Why?
|
| GTP-Binding Proteins | 9 | 1996 | 172 | 0.310 |
Why?
|
| Balloon Valvuloplasty | 2 | 2020 | 24 | 0.310 |
Why?
|
| Pregnancy Outcome | 6 | 2021 | 635 | 0.300 |
Why?
|
| Age Factors | 8 | 2024 | 2923 | 0.300 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2022 | 180 | 0.300 |
Why?
|
| Inpatients | 1 | 2013 | 553 | 0.290 |
Why?
|
| Magnetic Resonance Angiography | 4 | 2019 | 165 | 0.290 |
Why?
|
| Live Birth | 4 | 2021 | 72 | 0.290 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2021 | 79 | 0.280 |
Why?
|
| Cardiology | 3 | 2020 | 498 | 0.270 |
Why?
|
| Tachycardia, Supraventricular | 2 | 2022 | 106 | 0.270 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2025 | 3358 | 0.270 |
Why?
|
| Genetic Testing | 3 | 2024 | 1099 | 0.260 |
Why?
|
| Vascular Stiffness | 3 | 2019 | 81 | 0.260 |
Why?
|
| Fetal Diseases | 4 | 2024 | 461 | 0.260 |
Why?
|
| Genotype | 6 | 2024 | 2703 | 0.260 |
Why?
|
| Postoperative Complications | 7 | 2022 | 3139 | 0.250 |
Why?
|
| Fibrillin-1 | 5 | 2025 | 61 | 0.250 |
Why?
|
| Calcium Channel Blockers | 2 | 1996 | 118 | 0.250 |
Why?
|
| Filamins | 2 | 2017 | 27 | 0.240 |
Why?
|
| Heart Septal Defects, Ventricular | 2 | 2020 | 134 | 0.240 |
Why?
|
| Severity of Illness Index | 5 | 2025 | 3093 | 0.240 |
Why?
|
| Ultrasonography, Doppler | 3 | 2021 | 186 | 0.230 |
Why?
|
| Transforming Growth Factor beta3 | 1 | 2025 | 8 | 0.230 |
Why?
|
| Cause of Death | 2 | 2018 | 509 | 0.230 |
Why?
|
| Pilot Projects | 5 | 2023 | 1444 | 0.230 |
Why?
|
| Jaundice, Neonatal | 1 | 2004 | 10 | 0.220 |
Why?
|
| Losartan | 2 | 2020 | 35 | 0.220 |
Why?
|
| Parathyroid Hormone | 2 | 2008 | 83 | 0.220 |
Why?
|
| Coronary Vessels | 3 | 2019 | 549 | 0.210 |
Why?
|
| Incidence | 7 | 2017 | 3377 | 0.210 |
Why?
|
| Smad4 Protein | 1 | 2024 | 58 | 0.210 |
Why?
|
| Health Information Systems | 1 | 2024 | 32 | 0.210 |
Why?
|
| Animals | 35 | 2024 | 34850 | 0.210 |
Why?
|
| Elastin | 1 | 2024 | 31 | 0.210 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2018 | 1128 | 0.210 |
Why?
|
| Fetal Death | 2 | 2021 | 119 | 0.210 |
Why?
|
| Prospective Studies | 8 | 2022 | 6569 | 0.210 |
Why?
|
| Prevalence | 5 | 2024 | 2664 | 0.210 |
Why?
|
| Pulmonary Atresia | 2 | 2024 | 49 | 0.200 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2014 | 73 | 0.200 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 312 | 0.200 |
Why?
|
| Propensity Score | 1 | 2024 | 255 | 0.200 |
Why?
|
| Immunization | 1 | 2004 | 312 | 0.200 |
Why?
|
| RNA Splicing | 1 | 2024 | 247 | 0.200 |
Why?
|
| Supreme Court Decisions | 1 | 2022 | 17 | 0.200 |
Why?
|
| Fibrillins | 4 | 2022 | 30 | 0.190 |
Why?
|
| Palliative Care | 4 | 2020 | 456 | 0.190 |
Why?
|
| Disease Management | 2 | 2024 | 565 | 0.190 |
Why?
|
| American Heart Association | 1 | 2024 | 309 | 0.190 |
Why?
|
| DNA Copy Number Variations | 2 | 2018 | 1034 | 0.190 |
Why?
|
| Respiration, Artificial | 2 | 2024 | 504 | 0.190 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2024 | 578 | 0.190 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2014 | 215 | 0.190 |
Why?
|
| Ectopia Lentis | 1 | 2022 | 12 | 0.190 |
Why?
|
| Middle Aged | 15 | 2025 | 29027 | 0.190 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2020 | 84 | 0.180 |
Why?
|
| Sex Factors | 4 | 2020 | 1354 | 0.180 |
Why?
|
| Chromosome Deletion | 2 | 2021 | 656 | 0.180 |
Why?
|
| Obesity | 1 | 2013 | 2398 | 0.180 |
Why?
|
| Regression Analysis | 3 | 2018 | 796 | 0.180 |
Why?
|
| Medical Illustration | 1 | 2021 | 18 | 0.170 |
Why?
|
| Ataxia | 1 | 2022 | 177 | 0.170 |
Why?
|
| Ecchymosis | 1 | 2020 | 12 | 0.170 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 1444 | 0.170 |
Why?
|
| Rupture, Spontaneous | 1 | 2020 | 47 | 0.170 |
Why?
|
| Peritoneal Cavity | 1 | 2020 | 20 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2024 | 3853 | 0.170 |
Why?
|
| Follow-Up Studies | 10 | 2020 | 5412 | 0.170 |
Why?
|
| Hospital Charges | 1 | 2021 | 66 | 0.170 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2020 | 13 | 0.170 |
Why?
|
| Hernia, Inguinal | 1 | 2020 | 43 | 0.170 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2020 | 7 | 0.170 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 2020 | 42 | 0.170 |
Why?
|
| Vena Cava, Inferior | 1 | 2021 | 105 | 0.170 |
Why?
|
| Atenolol | 1 | 2020 | 44 | 0.170 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2023 | 214 | 0.160 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 20 | 0.160 |
Why?
|
| Herniorrhaphy | 1 | 2020 | 78 | 0.160 |
Why?
|
| Ductus Arteriosus | 1 | 2020 | 62 | 0.160 |
Why?
|
| Health Services Misuse | 1 | 2000 | 27 | 0.160 |
Why?
|
| Neurovascular Coupling | 1 | 2019 | 11 | 0.160 |
Why?
|
| Stakeholder Participation | 1 | 2020 | 32 | 0.160 |
Why?
|
| Bioethical Issues | 1 | 2019 | 23 | 0.160 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2000 | 77 | 0.160 |
Why?
|
| Hospitals, Urban | 1 | 2000 | 99 | 0.160 |
Why?
|
| Treatment Refusal | 1 | 2020 | 80 | 0.160 |
Why?
|
| Myocarditis | 1 | 2021 | 132 | 0.160 |
Why?
|
| Abdominal Injuries | 1 | 2020 | 117 | 0.160 |
Why?
|
| Critical Illness | 2 | 2022 | 618 | 0.150 |
Why?
|
| Isolated Noncompaction of the Ventricular Myocardium | 1 | 2019 | 44 | 0.150 |
Why?
|
| Signal Transduction | 7 | 2016 | 4720 | 0.150 |
Why?
|
| Accidental Falls | 1 | 2020 | 115 | 0.150 |
Why?
|
| Electrocardiography | 4 | 2019 | 996 | 0.150 |
Why?
|
| Defibrillators, Implantable | 1 | 2022 | 204 | 0.150 |
Why?
|
| Thulium | 1 | 2019 | 10 | 0.150 |
Why?
|
| Coronary Occlusion | 1 | 2019 | 32 | 0.150 |
Why?
|
| Proton-Translocating ATPases | 1 | 1999 | 18 | 0.150 |
Why?
|
| Prognosis | 5 | 2021 | 5016 | 0.150 |
Why?
|
| Lymphatic Vessels | 1 | 2019 | 36 | 0.150 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2020 | 126 | 0.150 |
Why?
|
| Case-Control Studies | 3 | 2018 | 3414 | 0.150 |
Why?
|
| Clinical Decision-Making | 2 | 2018 | 306 | 0.150 |
Why?
|
| Diastole | 2 | 2020 | 181 | 0.150 |
Why?
|
| Vacuolar Proton-Translocating ATPases | 1 | 1999 | 23 | 0.150 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2018 | 4 | 0.150 |
Why?
|
| Longevity | 1 | 2020 | 159 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2166 | 0.150 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2018 | 40 | 0.150 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2024 | 479 | 0.150 |
Why?
|
| Lymphatic Abnormalities | 1 | 2019 | 36 | 0.150 |
Why?
|
| Pulmonary Artery | 3 | 2025 | 463 | 0.150 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 305 | 0.150 |
Why?
|
| Coronary Circulation | 1 | 2019 | 206 | 0.140 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 1461 | 0.140 |
Why?
|
| Perinatal Care | 1 | 2019 | 68 | 0.140 |
Why?
|
| Truncus Arteriosus, Persistent | 1 | 2018 | 18 | 0.140 |
Why?
|
| Clinical Competence | 3 | 2017 | 1079 | 0.140 |
Why?
|
| Abdominal Pain | 1 | 2020 | 314 | 0.140 |
Why?
|
| Genetic Variation | 1 | 2025 | 1580 | 0.140 |
Why?
|
| Pulsatile Flow | 1 | 2018 | 124 | 0.140 |
Why?
|
| Vasodilator Agents | 3 | 2016 | 208 | 0.140 |
Why?
|
| Uterine Artery | 1 | 2018 | 29 | 0.140 |
Why?
|
| Mydriasis | 1 | 2018 | 8 | 0.140 |
Why?
|
| Tracheostomy | 1 | 2020 | 204 | 0.140 |
Why?
|
| Neck | 1 | 2019 | 142 | 0.140 |
Why?
|
| Heart-Assist Devices | 2 | 2019 | 1085 | 0.140 |
Why?
|
| Stents | 3 | 2019 | 874 | 0.140 |
Why?
|
| Eye Diseases, Hereditary | 1 | 2018 | 33 | 0.140 |
Why?
|
| Heart | 3 | 2017 | 689 | 0.140 |
Why?
|
| Fluorescent Dyes | 1 | 1999 | 264 | 0.140 |
Why?
|
| Esophageal Atresia | 1 | 2018 | 52 | 0.140 |
Why?
|
| Tracheoesophageal Fistula | 1 | 2018 | 48 | 0.140 |
Why?
|
| Transcription Factors | 2 | 2024 | 2491 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 1304 | 0.130 |
Why?
|
| Imidazoles | 1 | 1999 | 219 | 0.130 |
Why?
|
| Ventricular Function, Right | 2 | 2021 | 119 | 0.130 |
Why?
|
| Walking | 1 | 2019 | 233 | 0.130 |
Why?
|
| Pyridines | 1 | 1999 | 249 | 0.130 |
Why?
|
| Seizures | 1 | 2022 | 895 | 0.130 |
Why?
|
| Patient Participation | 1 | 2020 | 240 | 0.130 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 3018 | 0.130 |
Why?
|
| Pectus Carinatum | 1 | 2017 | 5 | 0.130 |
Why?
|
| Pacemaker, Artificial | 2 | 2017 | 188 | 0.130 |
Why?
|
| Ultrasonography, Interventional | 1 | 2019 | 208 | 0.130 |
Why?
|
| Cholera Toxin | 6 | 1994 | 51 | 0.130 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2020 | 248 | 0.130 |
Why?
|
| Pericardium | 1 | 2017 | 91 | 0.130 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 342 | 0.130 |
Why?
|
| Health Expenditures | 1 | 2018 | 132 | 0.130 |
Why?
|
| Arterio-Arterial Fistula | 1 | 2016 | 10 | 0.130 |
Why?
|
| Heart Conduction System | 1 | 2017 | 156 | 0.130 |
Why?
|
| Cyclic AMP | 3 | 1992 | 234 | 0.130 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2017 | 51 | 0.130 |
Why?
|
| Extracellular Matrix | 2 | 2014 | 237 | 0.130 |
Why?
|
| Myocardial Contraction | 2 | 2017 | 254 | 0.130 |
Why?
|
| Lung | 2 | 2021 | 1556 | 0.120 |
Why?
|
| Soluble Guanylyl Cyclase | 1 | 2016 | 7 | 0.120 |
Why?
|
| Heart Neoplasms | 1 | 2017 | 105 | 0.120 |
Why?
|
| Antifungal Agents | 2 | 2000 | 314 | 0.120 |
Why?
|
| Teratoma | 1 | 2017 | 129 | 0.120 |
Why?
|
| Laboratory Proficiency Testing | 1 | 2016 | 10 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2016 | 33 | 0.120 |
Why?
|
| Hemodynamics | 2 | 2017 | 861 | 0.120 |
Why?
|
| Pediatrics | 3 | 2017 | 1210 | 0.120 |
Why?
|
| Mutation, Missense | 1 | 2020 | 937 | 0.120 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2015 | 10 | 0.120 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2018 | 145 | 0.120 |
Why?
|
| Physicians | 1 | 2022 | 640 | 0.120 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 589 | 0.120 |
Why?
|
| Hypertension | 2 | 2016 | 1398 | 0.120 |
Why?
|
| Alprostadil | 1 | 2015 | 22 | 0.120 |
Why?
|
| Gene Expression Regulation | 3 | 2020 | 2442 | 0.120 |
Why?
|
| Moyamoya Disease | 1 | 2016 | 42 | 0.120 |
Why?
|
| Actins | 1 | 2018 | 334 | 0.120 |
Why?
|
| Esophageal Achalasia | 1 | 2016 | 46 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2017 | 456 | 0.120 |
Why?
|
| Atrioventricular Block | 1 | 2016 | 46 | 0.120 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 6 | 2001 | 34 | 0.120 |
Why?
|
| Aortography | 1 | 2016 | 183 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 2 | 2017 | 463 | 0.120 |
Why?
|
| Pneumocystis | 1 | 1994 | 10 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 670 | 0.110 |
Why?
|
| International Cooperation | 1 | 2015 | 167 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2017 | 247 | 0.110 |
Why?
|
| Hyperoxia | 1 | 2016 | 130 | 0.110 |
Why?
|
| Fracture Fixation | 1 | 2014 | 28 | 0.110 |
Why?
|
| Genetic Association Studies | 2 | 2017 | 857 | 0.110 |
Why?
|
| Echocardiography, Doppler | 1 | 2015 | 172 | 0.110 |
Why?
|
| Virulence Factors, Bordetella | 5 | 1994 | 23 | 0.110 |
Why?
|
| Respiration | 1 | 2015 | 123 | 0.110 |
Why?
|
| Heterozygote | 1 | 2016 | 715 | 0.110 |
Why?
|
| Cells, Cultured | 9 | 1999 | 3046 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 725 | 0.110 |
Why?
|
| Pertussis Toxin | 5 | 1994 | 27 | 0.110 |
Why?
|
| Prostheses and Implants | 1 | 2016 | 153 | 0.110 |
Why?
|
| Statistics as Topic | 1 | 2015 | 254 | 0.110 |
Why?
|
| Hibernation | 1 | 1993 | 2 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2020 | 554 | 0.110 |
Why?
|
| Aneurysm | 1 | 2014 | 82 | 0.100 |
Why?
|
| Mass Screening | 1 | 2019 | 830 | 0.100 |
Why?
|
| Tachycardia, Ventricular | 1 | 2016 | 211 | 0.100 |
Why?
|
| Tibial Fractures | 1 | 2014 | 63 | 0.100 |
Why?
|
| Internship and Residency | 2 | 2017 | 1258 | 0.100 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 826 | 0.100 |
Why?
|
| Primary Health Care | 1 | 2000 | 801 | 0.100 |
Why?
|
| Aged | 7 | 2025 | 21484 | 0.100 |
Why?
|
| Cardiac Volume | 1 | 2013 | 18 | 0.100 |
Why?
|
| Heart Arrest | 1 | 2017 | 375 | 0.100 |
Why?
|
| Comorbidity | 2 | 2016 | 1610 | 0.100 |
Why?
|
| Dogs | 3 | 2004 | 651 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2017 | 408 | 0.100 |
Why?
|
| Lung Transplantation | 1 | 2017 | 336 | 0.100 |
Why?
|
| Protozoan Proteins | 1 | 1994 | 134 | 0.100 |
Why?
|
| Nitric Oxide | 1 | 2016 | 470 | 0.100 |
Why?
|
| Kinetics | 7 | 2001 | 1130 | 0.100 |
Why?
|
| Education, Medical, Continuing | 1 | 2013 | 144 | 0.090 |
Why?
|
| Adenosine Diphosphate Ribose | 5 | 1993 | 13 | 0.090 |
Why?
|
| Survival Rate | 4 | 2019 | 2196 | 0.090 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2020 | 57 | 0.090 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 3761 | 0.090 |
Why?
|
| Adaptation, Physiological | 1 | 1993 | 272 | 0.090 |
Why?
|
| Emergency Service, Hospital | 1 | 2000 | 1171 | 0.090 |
Why?
|
| Inositol Phosphates | 2 | 2001 | 13 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 588 | 0.090 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 211 | 0.090 |
Why?
|
| Adenylate Cyclase Toxin | 4 | 1994 | 6 | 0.090 |
Why?
|
| Hospital Costs | 1 | 2013 | 187 | 0.090 |
Why?
|
| Protein Isoforms | 2 | 2024 | 422 | 0.090 |
Why?
|
| Microfilament Proteins | 2 | 2021 | 285 | 0.090 |
Why?
|
| Perinatal Mortality | 2 | 2020 | 44 | 0.080 |
Why?
|
| Peptides | 1 | 1994 | 844 | 0.080 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 902 | 0.080 |
Why?
|
| Exome | 2 | 2025 | 1087 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2013 | 1255 | 0.080 |
Why?
|
| Age of Onset | 2 | 2024 | 626 | 0.080 |
Why?
|
| Cardiovascular Diseases | 2 | 2019 | 2087 | 0.080 |
Why?
|
| Propranolol | 2 | 2022 | 112 | 0.080 |
Why?
|
| Organ Size | 2 | 2016 | 447 | 0.080 |
Why?
|
| Wounds and Injuries | 1 | 2013 | 394 | 0.080 |
Why?
|
| Observer Variation | 2 | 2023 | 306 | 0.080 |
Why?
|
| Congenital Abnormalities | 2 | 2024 | 299 | 0.070 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2008 | 31 | 0.070 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 1831 | 0.070 |
Why?
|
| Progestins | 1 | 2008 | 45 | 0.070 |
Why?
|
| Heart Failure | 1 | 2022 | 2398 | 0.070 |
Why?
|
| Quality of Life | 2 | 2020 | 2161 | 0.070 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2008 | 50 | 0.070 |
Why?
|
| Guanylyl Imidodiphosphate | 5 | 1994 | 6 | 0.070 |
Why?
|
| Calmodulin | 2 | 2000 | 208 | 0.070 |
Why?
|
| Edetic Acid | 1 | 1987 | 23 | 0.070 |
Why?
|
| Umbilical Veins | 3 | 1996 | 68 | 0.070 |
Why?
|
| Research Design | 2 | 2024 | 743 | 0.070 |
Why?
|
| Mitosporic Fungi | 2 | 2000 | 8 | 0.070 |
Why?
|
| Adenosine | 3 | 2001 | 135 | 0.070 |
Why?
|
| Europe | 2 | 2020 | 373 | 0.070 |
Why?
|
| Brain | 2 | 2018 | 3194 | 0.070 |
Why?
|
| Muscles | 1 | 1987 | 239 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2025 | 1500 | 0.070 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 3 | 1999 | 17 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2013 | 1700 | 0.060 |
Why?
|
| Mice | 11 | 2014 | 18507 | 0.060 |
Why?
|
| Isoproterenol | 6 | 1994 | 97 | 0.060 |
Why?
|
| Drainage | 2 | 2018 | 262 | 0.060 |
Why?
|
| Rats | 7 | 2000 | 3607 | 0.060 |
Why?
|
| Estrogens | 1 | 2008 | 436 | 0.060 |
Why?
|
| Bone Density | 1 | 2008 | 370 | 0.060 |
Why?
|
| Glucose Transport Proteins, Facilitative | 1 | 2025 | 22 | 0.060 |
Why?
|
| Health Services Research | 2 | 2013 | 187 | 0.060 |
Why?
|
| Infant, Premature, Diseases | 2 | 2020 | 252 | 0.060 |
Why?
|
| Fibrillin-2 | 1 | 2024 | 4 | 0.060 |
Why?
|
| Cardiac Myosins | 1 | 2024 | 11 | 0.060 |
Why?
|
| Adipokines | 1 | 2025 | 72 | 0.060 |
Why?
|
| Adenosine Diphosphate | 3 | 2001 | 55 | 0.060 |
Why?
|
| Salmonella Infections, Animal | 1 | 2004 | 6 | 0.060 |
Why?
|
| Chickenpox Vaccine | 1 | 2004 | 14 | 0.060 |
Why?
|
| Measles Vaccine | 1 | 2004 | 13 | 0.060 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2004 | 19 | 0.060 |
Why?
|
| Animals, Domestic | 1 | 2004 | 33 | 0.060 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2024 | 64 | 0.060 |
Why?
|
| Bites and Stings | 1 | 2004 | 27 | 0.050 |
Why?
|
| Myosin Heavy Chains | 1 | 2024 | 70 | 0.050 |
Why?
|
| Clubfoot | 1 | 2024 | 21 | 0.050 |
Why?
|
| Hyperbilirubinemia | 1 | 2004 | 42 | 0.050 |
Why?
|
| Hospitals, General | 1 | 2024 | 24 | 0.050 |
Why?
|
| Curriculum | 3 | 2017 | 765 | 0.050 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2014 | 24 | 0.050 |
Why?
|
| Cryptorchidism | 1 | 2024 | 37 | 0.050 |
Why?
|
| Ionophores | 2 | 1998 | 11 | 0.050 |
Why?
|
| Massachusetts | 1 | 2024 | 132 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2013 | 576 | 0.050 |
Why?
|
| Rotavirus Vaccines | 1 | 2004 | 73 | 0.050 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2014 | 50 | 0.050 |
Why?
|
| Facies | 1 | 2024 | 156 | 0.050 |
Why?
|
| Whooping Cough | 1 | 2004 | 61 | 0.050 |
Why?
|
| Bilirubin | 1 | 2004 | 128 | 0.050 |
Why?
|
| Genomics | 2 | 2025 | 1652 | 0.050 |
Why?
|
| Rabbits | 1 | 2004 | 673 | 0.050 |
Why?
|
| Hand Deformities, Congenital | 1 | 2024 | 94 | 0.050 |
Why?
|
| Patient Readmission | 2 | 2020 | 425 | 0.050 |
Why?
|
| Immune Sera | 2 | 1994 | 89 | 0.050 |
Why?
|
| Growth Disorders | 1 | 2024 | 191 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 1994 | 2553 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 309 | 0.050 |
Why?
|
| Fellowships and Scholarships | 2 | 2017 | 325 | 0.050 |
Why?
|
| Biological Variation, Population | 1 | 2022 | 26 | 0.050 |
Why?
|
| Cytosol | 2 | 1999 | 144 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2024 | 473 | 0.050 |
Why?
|
| Acute Disease | 3 | 1996 | 1163 | 0.050 |
Why?
|
| Blotting, Western | 2 | 1994 | 1080 | 0.050 |
Why?
|
| Adenylyl Cyclase Inhibitors | 2 | 1993 | 7 | 0.040 |
Why?
|
| Platelet Activation | 1 | 2001 | 69 | 0.040 |
Why?
|
| Tyrosine | 1 | 2001 | 148 | 0.040 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2001 | 65 | 0.040 |
Why?
|
| Blood Flow Velocity | 2 | 2020 | 440 | 0.040 |
Why?
|
| Amino Acid Sequence | 3 | 1994 | 2669 | 0.040 |
Why?
|
| Women's Health | 1 | 2022 | 148 | 0.040 |
Why?
|
| Guanosine Triphosphate | 3 | 1993 | 45 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2024 | 569 | 0.040 |
Why?
|
| Mice, Inbred Strains | 2 | 1994 | 308 | 0.040 |
Why?
|
| Geography | 1 | 2021 | 123 | 0.040 |
Why?
|
| Chromosome Mapping | 3 | 2016 | 1096 | 0.040 |
Why?
|
| Cell Membrane Permeability | 3 | 2000 | 72 | 0.040 |
Why?
|
| Constriction | 1 | 2020 | 47 | 0.040 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2022 | 217 | 0.040 |
Why?
|
| In Vitro Techniques | 2 | 1993 | 862 | 0.040 |
Why?
|
| Pneumonia | 1 | 2004 | 334 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 1994 | 3771 | 0.040 |
Why?
|
| Indomethacin | 1 | 2020 | 82 | 0.040 |
Why?
|
| Ibuprofen | 1 | 2020 | 41 | 0.040 |
Why?
|
| Binding, Competitive | 3 | 2001 | 161 | 0.040 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2020 | 13 | 0.040 |
Why?
|
| Canada | 1 | 2021 | 337 | 0.040 |
Why?
|
| Life Tables | 1 | 2000 | 28 | 0.040 |
Why?
|
| Cell Line | 3 | 2001 | 2724 | 0.040 |
Why?
|
| Saponins | 1 | 2000 | 23 | 0.040 |
Why?
|
| New York City | 1 | 2000 | 65 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 413 | 0.040 |
Why?
|
| Holistic Health | 1 | 2020 | 12 | 0.040 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2020 | 51 | 0.040 |
Why?
|
| Triterpenes | 1 | 2000 | 24 | 0.040 |
Why?
|
| Social Class | 1 | 2021 | 207 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 3995 | 0.040 |
Why?
|
| Prenatal Care | 1 | 2022 | 359 | 0.040 |
Why?
|
| Subcellular Fractions | 1 | 1999 | 90 | 0.040 |
Why?
|
| Prazosin | 2 | 1996 | 16 | 0.040 |
Why?
|
| Biopsy | 1 | 2023 | 1288 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2023 | 559 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 1999 | 61 | 0.040 |
Why?
|
| Influenza Vaccines | 1 | 2004 | 498 | 0.040 |
Why?
|
| North America | 1 | 2020 | 265 | 0.040 |
Why?
|
| Radiography | 2 | 2014 | 819 | 0.040 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2022 | 274 | 0.040 |
Why?
|
| Scintillation Counting | 1 | 1999 | 6 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2000 | 761 | 0.040 |
Why?
|
| Type C Phospholipases | 1 | 1999 | 21 | 0.040 |
Why?
|
| Baculoviridae | 1 | 1999 | 60 | 0.040 |
Why?
|
| Bradykinin | 2 | 1989 | 50 | 0.040 |
Why?
|
| Infant Care | 1 | 2019 | 47 | 0.040 |
Why?
|
| Anthropometry | 1 | 1999 | 194 | 0.040 |
Why?
|
| Bone Resorption | 1 | 1999 | 52 | 0.040 |
Why?
|
| Myocytes, Cardiac | 1 | 2014 | 652 | 0.040 |
Why?
|
| Insecta | 1 | 1999 | 64 | 0.040 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2021 | 253 | 0.040 |
Why?
|
| Osteoclasts | 1 | 1999 | 72 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2020 | 240 | 0.040 |
Why?
|
| Parturition | 1 | 2019 | 66 | 0.040 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2018 | 57 | 0.040 |
Why?
|
| Mitral Valve Stenosis | 1 | 2018 | 39 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 2451 | 0.040 |
Why?
|
| Arterial Pressure | 1 | 2019 | 127 | 0.040 |
Why?
|
| Valinomycin | 1 | 1998 | 1 | 0.040 |
Why?
|
| Nigericin | 1 | 1998 | 3 | 0.040 |
Why?
|
| Thapsigargin | 1 | 1998 | 23 | 0.040 |
Why?
|
| Monensin | 1 | 1998 | 11 | 0.040 |
Why?
|
| Protein Binding | 2 | 2000 | 1734 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2000 | 333 | 0.040 |
Why?
|
| Biological Transport, Active | 1 | 1998 | 76 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2020 | 225 | 0.030 |
Why?
|
| Terpenes | 1 | 1998 | 30 | 0.030 |
Why?
|
| Microsomes | 1 | 1997 | 40 | 0.030 |
Why?
|
| Chromosomes, Human, X | 1 | 2018 | 158 | 0.030 |
Why?
|
| MEDLINE | 1 | 2017 | 20 | 0.030 |
Why?
|
| Norwood Procedures | 1 | 2019 | 105 | 0.030 |
Why?
|
| Birth Weight | 2 | 2015 | 351 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2017 | 2851 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 2018 | 131 | 0.030 |
Why?
|
| Cerebellum | 2 | 2000 | 464 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2019 | 301 | 0.030 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 46 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2018 | 144 | 0.030 |
Why?
|
| Inheritance Patterns | 1 | 2017 | 131 | 0.030 |
Why?
|
| Medical Records | 1 | 2018 | 189 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2017 | 141 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2020 | 337 | 0.030 |
Why?
|
| Hydrops Fetalis | 1 | 2017 | 85 | 0.030 |
Why?
|
| Microcirculation | 3 | 1996 | 117 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2019 | 487 | 0.030 |
Why?
|
| Diltiazem | 1 | 1996 | 14 | 0.030 |
Why?
|
| Diseases in Twins | 1 | 2017 | 97 | 0.030 |
Why?
|
| Drosophila | 1 | 2001 | 824 | 0.030 |
Why?
|
| Intellectual Disability | 1 | 2024 | 1094 | 0.030 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1996 | 43 | 0.030 |
Why?
|
| Stillbirth | 1 | 2017 | 103 | 0.030 |
Why?
|
| Mental Health | 1 | 2020 | 377 | 0.030 |
Why?
|
| Japan | 1 | 2016 | 156 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2017 | 229 | 0.030 |
Why?
|
| Australia | 1 | 2016 | 185 | 0.030 |
Why?
|
| Sf9 Cells | 1 | 2016 | 10 | 0.030 |
Why?
|
| Allografts | 1 | 2017 | 196 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2018 | 286 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2016 | 52 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2000 | 571 | 0.030 |
Why?
|
| Colforsin | 3 | 1993 | 51 | 0.030 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 3 | 2001 | 11 | 0.030 |
Why?
|
| Birthing Centers | 1 | 2015 | 9 | 0.030 |
Why?
|
| Heart Septal Defects | 1 | 2016 | 44 | 0.030 |
Why?
|
| Causality | 1 | 2016 | 94 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 1841 | 0.030 |
Why?
|
| Alleles | 1 | 2020 | 1685 | 0.030 |
Why?
|
| Aorta, Abdominal | 1 | 2016 | 118 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2016 | 131 | 0.030 |
Why?
|
| Abortion, Eugenic | 1 | 2015 | 9 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 1999 | 2680 | 0.030 |
Why?
|
| Arginine | 1 | 2018 | 343 | 0.030 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2017 | 260 | 0.030 |
Why?
|
| Computed Tomography Angiography | 1 | 2017 | 215 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1999 | 1671 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1161 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1996 | 223 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 327 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 256 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 437 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 1423 | 0.030 |
Why?
|
| Pericardial Effusion | 1 | 2015 | 72 | 0.030 |
Why?
|
| Spectrometry, Mass, Fast Atom Bombardment | 1 | 1994 | 2 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2016 | 231 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1575 | 0.030 |
Why?
|
| External Fixators | 1 | 2014 | 14 | 0.030 |
Why?
|
| Conscious Sedation | 1 | 2015 | 60 | 0.030 |
Why?
|
| Bone Plates | 1 | 2014 | 26 | 0.030 |
Why?
|
| Precipitin Tests | 1 | 1994 | 143 | 0.030 |
Why?
|
| Fermentation | 1 | 1994 | 69 | 0.030 |
Why?
|
| Dexamethasone | 2 | 1993 | 273 | 0.030 |
Why?
|
| Peptides, Cyclic | 1 | 1994 | 52 | 0.030 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1994 | 36 | 0.030 |
Why?
|
| Echinocandins | 1 | 1994 | 44 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2000 | 674 | 0.030 |
Why?
|
| Marmota | 1 | 1993 | 3 | 0.030 |
Why?
|
| Airway Obstruction | 1 | 2016 | 167 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 600 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2014 | 127 | 0.030 |
Why?
|
| Fracture Fixation, Internal | 1 | 2014 | 83 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 714 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2018 | 780 | 0.030 |
Why?
|
| Thionucleotides | 2 | 1992 | 23 | 0.030 |
Why?
|
| Helminth Proteins | 1 | 1994 | 103 | 0.030 |
Why?
|
| Homeostasis | 1 | 1998 | 722 | 0.030 |
Why?
|
| Molecular Structure | 1 | 1994 | 322 | 0.030 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2013 | 53 | 0.030 |
Why?
|
| Learning Curve | 1 | 2013 | 57 | 0.020 |
Why?
|
| Child Mortality | 1 | 2013 | 24 | 0.020 |
Why?
|
| Candidiasis | 1 | 1994 | 137 | 0.020 |
Why?
|
| Microscopy, Electron | 2 | 1996 | 340 | 0.020 |
Why?
|
| Parents | 1 | 2020 | 1080 | 0.020 |
Why?
|
| Cost Savings | 1 | 2013 | 78 | 0.020 |
Why?
|
| Tretinoin | 1 | 1993 | 102 | 0.020 |
Why?
|
| Norepinephrine | 2 | 1994 | 166 | 0.020 |
Why?
|
| Pulmonary Circulation | 1 | 2013 | 117 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2013 | 209 | 0.020 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 1992 | 20 | 0.020 |
Why?
|
| Hypothalamus | 1 | 1993 | 212 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 1992 | 101 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1966 | 0.020 |
Why?
|
| Iodocyanopindolol | 1 | 1991 | 3 | 0.020 |
Why?
|
| Pindolol | 1 | 1991 | 4 | 0.020 |
Why?
|
| Trypanosoma | 1 | 1991 | 10 | 0.020 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2018 | 659 | 0.020 |
Why?
|
| Estradiol | 1 | 1993 | 488 | 0.020 |
Why?
|
| Enzyme Activation | 2 | 1993 | 618 | 0.020 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 1990 | 15 | 0.020 |
Why?
|
| Heart Rate | 1 | 1994 | 584 | 0.020 |
Why?
|
| Mitogens | 1 | 1990 | 31 | 0.020 |
Why?
|
| Heparitin Sulfate | 1 | 1990 | 20 | 0.020 |
Why?
|
| Platelet Adhesiveness | 1 | 1990 | 38 | 0.020 |
Why?
|
| Proteoglycans | 1 | 1990 | 92 | 0.020 |
Why?
|
| Host-Parasite Interactions | 1 | 1990 | 82 | 0.020 |
Why?
|
| Platelet Aggregation | 1 | 1990 | 106 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 1993 | 263 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 821 | 0.020 |
Why?
|
| Critical Care | 1 | 2015 | 687 | 0.020 |
Why?
|
| Cell Membrane | 2 | 1993 | 472 | 0.020 |
Why?
|
| Infant, Premature | 1 | 2015 | 843 | 0.020 |
Why?
|
| Advanced Cardiac Life Support | 1 | 2009 | 17 | 0.020 |
Why?
|
| Phlebotomy | 1 | 2009 | 20 | 0.020 |
Why?
|
| Boston | 1 | 2009 | 123 | 0.020 |
Why?
|
| Spinal Puncture | 1 | 2009 | 52 | 0.020 |
Why?
|
| Biomarkers | 1 | 2019 | 3404 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 1996 | 1037 | 0.020 |
Why?
|
| Chronic Disease | 2 | 1990 | 1233 | 0.020 |
Why?
|
| Vascular Diseases | 1 | 1990 | 150 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 113 | 0.020 |
Why?
|
| Calcium Signaling | 2 | 2001 | 254 | 0.020 |
Why?
|
| Femur Neck | 1 | 2008 | 15 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 1992 | 356 | 0.020 |
Why?
|
| Oligomycins | 1 | 1988 | 5 | 0.020 |
Why?
|
| Ionomycin | 1 | 1988 | 18 | 0.020 |
Why?
|
| Ethers | 1 | 1988 | 9 | 0.020 |
Why?
|
| Stimulation, Chemical | 1 | 1988 | 43 | 0.020 |
Why?
|
| Ribose | 1 | 1988 | 13 | 0.020 |
Why?
|
| Cations, Divalent | 1 | 1988 | 21 | 0.020 |
Why?
|
| Bone Remodeling | 1 | 2008 | 56 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2013 | 988 | 0.020 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2016 | 787 | 0.020 |
Why?
|
| Spinal Fractures | 1 | 2008 | 46 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1987 | 219 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 2008 | 113 | 0.020 |
Why?
|
| Catheterization, Peripheral | 1 | 2009 | 131 | 0.020 |
Why?
|
| Angiotensin II | 1 | 1988 | 163 | 0.020 |
Why?
|
| Acetylcholine | 1 | 1987 | 84 | 0.020 |
Why?
|
| Species Specificity | 1 | 1987 | 542 | 0.020 |
Why?
|
| Disease Models, Animal | 3 | 1996 | 4690 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 7140 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 2 | 2000 | 1045 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 1177 | 0.010 |
Why?
|
| Cattle | 2 | 1997 | 569 | 0.010 |
Why?
|
| Radiation Hybrid Mapping | 1 | 2002 | 6 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 2002 | 81 | 0.010 |
Why?
|
| Synteny | 1 | 2002 | 78 | 0.010 |
Why?
|
| LIM Domain Proteins | 1 | 2002 | 64 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2002 | 71 | 0.010 |
Why?
|
| Thromboxane A2 | 1 | 2001 | 14 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 2001 | 21 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 2001 | 52 | 0.010 |
Why?
|
| Zebrafish Proteins | 1 | 2002 | 129 | 0.010 |
Why?
|
| Dimerization | 1 | 2001 | 149 | 0.010 |
Why?
|
| Acetates | 1 | 2001 | 80 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2001 | 115 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2001 | 235 | 0.010 |
Why?
|
| Cricetinae | 1 | 2001 | 381 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 282 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2002 | 774 | 0.010 |
Why?
|
| Serotonin | 1 | 2001 | 212 | 0.010 |
Why?
|
| Mammals | 1 | 2001 | 271 | 0.010 |
Why?
|
| Ligands | 1 | 2001 | 495 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2002 | 380 | 0.010 |
Why?
|
| Carbohydrate Conformation | 1 | 2000 | 15 | 0.010 |
Why?
|
| Spodoptera | 1 | 1999 | 43 | 0.010 |
Why?
|
| Muscle Proteins | 1 | 2002 | 404 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2001 | 826 | 0.010 |
Why?
|
| Animals, Newborn | 2 | 1994 | 1033 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2001 | 289 | 0.010 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2000 | 159 | 0.010 |
Why?
|
| Binding Sites | 1 | 2001 | 1256 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2000 | 297 | 0.010 |
Why?
|
| Models, Structural | 1 | 1997 | 47 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2002 | 1050 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2000 | 827 | 0.010 |
Why?
|
| Microscopy, Video | 1 | 1996 | 20 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 1350 | 0.010 |
Why?
|
| Models, Neurological | 1 | 1997 | 216 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2000 | 1612 | 0.010 |
Why?
|
| Spasm | 1 | 1996 | 48 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2001 | 1036 | 0.010 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1994 | 8 | 0.010 |
Why?
|
| Uncoupling Agents | 1 | 1993 | 5 | 0.010 |
Why?
|
| Preoptic Area | 1 | 1993 | 12 | 0.010 |
Why?
|
| Ovariectomy | 1 | 1993 | 170 | 0.010 |
Why?
|
| Temperature | 1 | 1994 | 302 | 0.010 |
Why?
|
| Sodium Fluoride | 1 | 1993 | 8 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1994 | 448 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1993 | 252 | 0.010 |
Why?
|
| Contraindications | 1 | 1992 | 77 | 0.010 |
Why?
|
| Inulin | 1 | 1992 | 18 | 0.010 |
Why?
|
| Bucladesine | 1 | 1992 | 19 | 0.010 |
Why?
|
| Liver | 1 | 2000 | 1797 | 0.010 |
Why?
|
| Sorbitol | 1 | 1992 | 9 | 0.010 |
Why?
|
| Receptors, Thrombin | 1 | 1992 | 14 | 0.010 |
Why?
|
| Thrombin | 1 | 1992 | 59 | 0.010 |
Why?
|
| Serum Albumin | 1 | 1992 | 116 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1994 | 605 | 0.010 |
Why?
|
| Thromboxane B2 | 1 | 1990 | 17 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1993 | 1224 | 0.010 |
Why?
|
| Epoprostenol | 1 | 1990 | 44 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 1992 | 292 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1990 | 136 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1989 | 118 | 0.000 |
Why?
|
| Receptors, Cell Surface | 1 | 1992 | 451 | 0.000 |
Why?
|
| Nervous System Diseases | 1 | 1992 | 412 | 0.000 |
Why?
|
| Fibrosis | 1 | 1989 | 421 | 0.000 |
Why?
|
| Blood Platelets | 1 | 1990 | 323 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1989 | 1653 | 0.000 |
Why?
|